



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	283649	REDORMIN FORTE
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	SFI Australasia	
<b>Postal Address</b>	PO Box 1027, CROWS NEST, NSW, 1585 Australia	
<b>ARTG Start Date</b>	15/12/2016	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . REDORMIN FORTE

Product Type	Single Medicine Product	Effective Date	18/10/2019
--------------	-------------------------	----------------	------------

### Permitted Indications

- Helps enhance/promote healthy nerve conduction/transmission/neurotransmission
- Traditionally used in Western herbal medicine to soporific/induces sleep
- Enhance/promote/increase refreshing sleep
- Traditionally used in Western herbal medicine to decrease/reduce/relieve sleeplessness
- Decrease/reduce/relieve sleeplessness
- Decrease/reduce time to fall asleep
- Decrease/reduce/relieve disturbed/restless sleep
- Traditionally used in Western herbal medicine to decrease/reduce/relieve disturbed/restless sleep
- Enhance/promote/increase healthy sleep patterns
- Maintain/support healthy sleeping patterns
- Enhance/improve/promote/increase sleep quality/deep sleep
- Traditionally used in Western herbal medicine to enhance/improve/promote/increase sleep quality/deep sleep
- Help establish/restore/reset sleep-wake cycle (circadian rhythm)

### Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

### Standard Indications

No Standard Indications included on Record

### Specific Indications



Australian Government  
Department of Health and Aged Care  
Therapeutic Goods Administration

No Specific Indications included on Record

**Warnings**

If symptoms persist consult your healthcare practitioner (or words to that effect).

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form** Tablet, film coated

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

<b>Humulus lupulus flower Extract dry concentrate</b>	<b>120 mg</b>
Equivalent: Humulus lupulus (Dry)	720 mg
<b>Valeriana officinalis root Extract dry concentrate</b>	<b>500 mg</b>
Equivalent: Valeriana officinalis (Dry)	2.5 g

**Other Ingredients (Excipients)**

colloidal anhydrous silica

croscarmellose sodium

hypromellose

indigo carmine

macrogol 20000

magnesium stearate

microcrystalline cellulose

stearic acid

titanium dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary